Woodline Partners’s Eupraxia Pharmaceuticals EPRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$6.8M Hold
746,864
– – 0.02% 647
2026
Q2
$4.94M Buy
746,864
+306,313
+70% +$2.11M 0.02% 693
2026
Q1
$3.19M Buy
+440,551
New +$3.55M 0.01% 739

Other funds holding EPRX

Woodline Partners's EPRX Position: Q3 2026 in Review

Woodline Partners held its Eupraxia Pharmaceuticals (EPRX) position steady in Q3 2026 at 746,864 shares worth $6.8M. The position accounts for 0.02% of the portfolio, ranked #647.

Woodline Partners first reported a position in EPRX in Q1 2026 and has held it in 3 quarters since. 70 funds tracked by Wall St. Rank hold EPRX as of Q3 2026.

  • Woodline Partners held 746,864 shares of Eupraxia Pharmaceuticals worth $6.8M as of Q3 2026.
  • Woodline Partners left its Eupraxia Pharmaceuticals share count unchanged in Q3 2026.
  • Eupraxia Pharmaceuticals made up 0.02% of Woodline Partners's portfolio in Q3 2026, its #647 holding.
  • Woodline Partners first reported a position in Eupraxia Pharmaceuticals in Q1 2026 and has held it in 3 quarters since.
  • 70 funds tracked by Wall St. Rank held Eupraxia Pharmaceuticals as of Q3 2026.

Based on Woodline Partners's 13F filing for Q3 2026, filed 16 Nov 2026.